The abstract is read at the publisher; the summary is JClub's.
Mitiperstat 5 mg once daily did not improve time to first COPDCompEx event over 24 weeks in adults with moderate-to-severe COPD at high exacerbation risk.
- Why it matters: Neutrophilic inflammation is common in COPD, and targeting myeloperoxidase expressed in neutrophils was expected to reduce exacerbations and improve lung function.
- What they did: In the phase 2a CRESCENDO trial, 381 adults (40–80 years) on dual or triple inhaled therapy were randomized to mitiperstat or placebo for up to 24 weeks, with COPDCompEx as the primary endpoint.
- The result: COPDCompEx events occurred in 125 (66.1%) versus 125 (65.1%) participants, with no benefit versus placebo (HR 1.07, 90% CI 0.87–1.32; p=0.599), and pneumonia was reported in 7 versus 2 participants.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.